Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

Christian Marth*, Rafal Tarnawski, Alexandra Tyulyandina, Sandro Pignata, Lucy Gilbert, Diego Kaen, M. Jesús Rubio, Sophia Frentzas, Mario Beiner, Manuel Magallanes-Maciel, Laura Farrelly, Chel Hun Choi, Regina Berger, Christine Lee, Christof Vulsteke, Kosei Hasegawa, Elena Ioanna Braicu, Xiaohua Wu, Jodi McKenzie, John J. LeeVicky Makker

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry